When: Weekly close above $415

Then: Add final 20% of intended position

Conditional BUY with deferred entry, reduced sizing, and strict technical confirmation triggers

• 200 SMA at $356 is not guaranteed support; if broken on weekly close, downside could be 12-15% to next support
• September intraday low of $374, lower Bollinger band at $358
• MACD histogram improvement from negative 921 to negative 748 represents slowing deterioration, not bullish signal
• Net debt of $43 billion vs annualized FCF of $14 billion means 3 years to pay down if all goes right
• 4.9x debt to equity is concerning in higher-for-longer rate regime
• Market pricing 84% odds of another hike and 62% probability of second hike after that
• Prolia biosimilar erosion cycle will compound through 2026-2027
• Pelacarsen selloff on September 4th was worst single-day decline in over two decades for AMGN
• Wait for daily close above 10 EMA at $391.55 on volume exceeding 4 million shares, OR successful retest/hold of 200 SMA region at $356-$360 with bullish reversal candle
• Deploy 25% of intended overweight on first confirmation trigger
• Add second tranche (50% of intended size) on daily close above 50 SMA at $398
• Add final 25% on weekly close above $415 breakdown level
• Stop loss at $362 (approximately 4.7% downside from current levels)
• Total exposure capped at 50% of intended overweight until earnings validate deleveraging trajectory and Prolia erosion tracks within consensus
• Invalidation: weekly close below 200 SMA, second Lp(a) class readout disappointment from any sponsor, or Prolia erosion accelerating beyond consensus
• Q2 2026 was genuine breakout: revenue crossed $10 billion, operating margins expanded 600 basis points, EPS grew 65% year-over-year

→ vs aggressive: 5:1 reward-to-risk ratio is built on asymmetric assumption that 200 SMA at $356 holds; if it breaks on weekly close, downside is not 6% but 12-15% to next support (September intraday low of $374, lower Bollinger band at $358)

→ vs aggressive: 6.8M shares flushed on breakdown day followed by 2-3M share sessions shows distribution absorbed without follow-through buying, not necessarily accumulation; absence of follow-through selling is not the same as presence of a bid

→ vs aggressive: MACD histogram improvement from negative 921 to negative 748 is slowing deterioration, not a bullish signal; same readings have preceded major breakdowns of last 40 years

→ vs aggressive: 4.9x debt to equity is not a fortress; higher-for-longer regime directly increases debt service costs and constrains deleveraging options through slower M&A and tighter secondary equity issuance

→ vs aggressive: Pelacarsen selloff was worst single-day decline in over two decades for AMGN; that kind of move often marks regime change, not an overreaction

→ vs aggressive: Initial tranche at $380 violates first principle of not committing capital before confirmation when medium-term trend is broken and MACD has not crossed bullish

→ vs aggressive: Building position in 2-4 weeks is too fast; 4-6 week build is more appropriate given technical damage

→ vs aggressive: Full overweight sizing before earnings validate trajectory risks whipsaw in a name with 4.9x debt-to-equity below every major moving average

→ vs neutral: HOLD is not a stance, it is a deferral; indefinite patience has its own opportunity cost in a name with constructive fundamentals, intact analyst targets, and clear technical roadmap

OVERWEIGHT

• Aggressive analyst's 5-to-1 risk-reward is flawed—the 200 SMA is not a floor; actual downside on a break could be closer to 30% to $270, not 6%
• MACD histogram improvement from negative 921 to negative 748 is NOT a bullish signal—it's slowing decline, not confirmation of reversal
• Aggressive analyst violates his own confirmation logic by committing capital at $380 before the required $391 confirmation trigger
• FCF of 14B against 43B net debt is manageable only if everything goes right—no MariTide disappointment, no Imdelltra stumbles, stable refinancing, no major M&A
• Pelacarsen overhang: 15% market cap decline on a drug AMGN doesn't own shouldn't be dismissed as fully absorbed after 8 trading days
• Conservative analyst's two scenarios ($391.55 confirmation OR $356 200 SMA retest) are separated by 10%—requiring the worst case to occur for one entry point
• Conservative sizing surrenders asymmetry—full Overweight not achieved until stock moves ~9% from current levels, compressing upside to 15-20%
• Conservative's 3-4 month cap at half exposure until earnings validation costs significant optionality
• Real support cluster is $358-$374 (lower Bollinger band, September intraday low, and 200 SMA converging)
• Proposed plan: 40% initial at $380, 40% on confirmation at $391.55 with volume above 4 million, 20% on weekly close above $415
• Active stop at $362 (below lower Bollinger band, ~4.5% downside from current levels)
• Structural invalidation at close below $356 on weekly basis—separate from the active stop
• Build time of 3-4 weeks is appropriate—not 2 weeks (too aggressive) and not 6 weeks (too much asymmetry surrendered)
• Do not cap at half exposure—reach full Overweight on the defined schedule, then cut to neutral only if Prolia erosion or Lp(a) readout disappoints
• Biggest risk is not taking the trade, and also taking it wrong—the middle path compounds

→ vs aggressive: Calls 6% downside to 200 SMA but that level is not a floor—if it breaks on weekly close, actual downside is closer to 30% to $270

→ vs aggressive: MACD histogram improvement from -921 to -748 is NOT a bullish signal—it's the rate of decline slowing, not confirmation of reversal

→ vs aggressive: Commits capital at $380 before the $391 confirmation he himself requires—this violates his own logic on position sizing

→ vs aggressive: Understates leverage risk—14B FCF vs 43B net debt trajectory requires everything to go right in a higher-for-longer rate regime

→ vs conservative: Two entry scenarios ($391.55 OR $356) are separated by 10%—one requires the worst case to occur, which is not a viable strategy

→ vs conservative: Sizing is overly restrictive—full Overweight not achieved until ~9% move from current levels, surrendering most of the asymmetry

→ vs conservative: Capping total exposure at half until earnings validation costs too much optionality in a name with intact targets and macro tailwind

→ vs conservative: Both analysts incorrectly treat 200 SMA as the only meaningful support—real support cluster is $358-$374